For 2026, Alkermes guided total revenues of $1.73 billion to $1.84 billion, including proprietary product net sales of $1.52 billion to $1.60 billion. It expects manufacturing and royalty revenues of $210 million to $240 million, reflecting scheduled expiration of certain XEPLION royalties that phase out on a country-by-country basis in the second half of 2026. The company also noted that its VUMERITY manufacturing obligations were completed in 2025, with future VUMERITY revenue expected to be solely royalt ...